Searched for
ALEMBIC PHARMACEUTICALS SHARE PRICE TARGET
API prices fall as West Asia tensions ease, boosting Indian pharma sectorPrices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West...- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Stock Radar: MRPL bounces back after forming double bottom formation; stock still down 25% from highs – should you buy?Mangalore Refinery and Petrochemicals Ltd stock is showing positive signals. A double bottom formation on daily charts indicates a potentia...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Stock Radar: Why TMPV is a good long term buy at current levels; stock rallies over 20% in last 3 monthsTata Motors Passenger Vehicles Ltd (TMPV) is showing signs of a comeback, bouncing strongly from multi-year lows around the ₹190-210 suppor...
- Nomura raises Adani Ports share price target by 12%. Here are 3 major reasons whyNomura has raised its target price on Adani Ports and Special Economic Zone to Rs 2,080 from Rs 1,850, while retaining its Buy rating. The ...
- RIL shares jump 6% in 3 days, market cap soars by Rs 1 lakh cr ahead of AGM. Why Morgan Stanley still sees 38% upsideReliance Industries has added over Rs 1 lakh crore in market value in just three trading sessions ahead of its closely watched AGM. Despite...
- Leapfrog Engineering Services IPO to open on Wed at Rs 21-23 per shareLeapfrog Engineering Services Ltd has set its IPO price band at Rs 21-23 per share, opening for subscription on June 17, 2026. The Rs 88.51...
- Suzlon Energy shares jump 3%: Why brokers see up to 36% upside for ‘most investible Indian wind player’Suzlon Energy shares rose 3% after management unveiled an ambitious FY31 growth roadmap at its Investor Day. The company plans to evolve fr...
- Buy, Sell or Hold: RIL remains Morgan Stanley's top pick; remains underweight on Oil IndiaBrokerages remain selective on India's energy sector, favouring companies with strong growth drivers and attractive valuations. Morgan Stan...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Stock Radar: Nestle India stock gives a breakout from a falling channel trendline; time to buy?Nestle India Ltd has broken out of a falling channel resistance on daily charts, signaling potential for further gains. Experts suggest sho...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Honasa shares jump 6% on Rs 5,500 crore revenue target by FY31. What is Goldman Sachs saying?Honasa Consumer shares surged after the company outlined a revenue target of ₹5,500 crore by FY31. The guidance implies an annual growth ra...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
Load More
